Lipid accumulation and transforming growth factor-beta upregulation in the kidneys of rats administered angiotensin II

Hypertension. 2005 Nov;46(5):1180-5. doi: 10.1161/01.HYP.0000184653.75036.d5. Epub 2005 Oct 3.

Abstract

Abnormal lipid metabolism may play a role in progressive renal failure. We studied whether lipid accumulation occurs and whether lipid deposits are colocalized with transforming growth factor-beta1 (TGF-beta1) in the kidney of angiotensin II-infused animals. Oil red O staining showed marked lipid deposition in the tubular epithelial and vascular wall cells of angiotensin II-treated but not in norepinephrine-treated rats. Histological analyses showed that increased amounts of superoxide and intense TGF-beta1 mRNA expression were present in lipid-positive tubular epithelial cells in angiotensin II-infused animals. Protein expression of sterol regulatory element-binding protein 1 (SREBP-1) and mRNA expression of fatty acid synthase in the kidney were &3 times and 1.5 times, respectively, higher in angiotensin II-treated rats than in controls. Treatment of angiotensin II-infused animals with an iron chelator, deferoxamine, attenuated the angiotensin II-induced increases in renal expression of SREBP-1 and fatty acid synthase and normalized the lipid content in the renal cortical tissues. Abnormal lipid metabolism may be associated with upregulation of TGF-beta1 expression and aberrant iron homeostasis in the kidneys of angiotensin II-infused animals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology*
  • Animals
  • Deferoxamine / pharmacology
  • Fatty Acid Synthases / genetics
  • Gene Expression Regulation
  • In Situ Hybridization
  • Iron / metabolism
  • Iron Chelating Agents / pharmacology
  • Kidney / metabolism*
  • Lipid Metabolism / drug effects*
  • Lipid Metabolism / genetics
  • Lipids / blood
  • Male
  • Plasminogen Activator Inhibitor 1 / genetics
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Staining and Labeling
  • Sterol Regulatory Element Binding Protein 1 / antagonists & inhibitors
  • Sterol Regulatory Element Binding Protein 1 / metabolism
  • Superoxides / metabolism
  • Tissue Distribution
  • Transforming Growth Factor beta / metabolism*
  • Transforming Growth Factor beta1
  • Up-Regulation / drug effects*

Substances

  • Iron Chelating Agents
  • Lipids
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Srebf1 protein, rat
  • Sterol Regulatory Element Binding Protein 1
  • Tgfb1 protein, rat
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
  • Superoxides
  • Angiotensin II
  • Iron
  • Fatty Acid Synthases
  • Deferoxamine